Home Companies Catalysts Deep Dives
Patritumab deruxtecan HER3-DXd PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Launch2024-10-04
US LOE2039-01-01
Peak Sales Est$3000M
Formulations[{"id":"patritumab-iv","doses":"100mg vial","route":"IV","setting":"INFUSION_CENTER","frequency":"Ev
Companies
DSNKY (ORIGINATOR)50%
AZN (CO_DEVELOPER)50%
Mechanism: HER3-directed (DXd payload)
Expert: Patritumab-based anti-HER3 ADC with DXd payload. HER3 upregulation is a key resistance mechanism to EGFR TKIs, enabling targeted therapy for TKI-refractory EGFR-mutant NSCLC.
Everyday: An antibody-drug conjugate that targets HER3 protein, particularly effective in lung cancers that have become resistant to other targeted therapies.
Targets: ["HER3"]
Revenue History
PeriodRevenue ($M)
Q4 2024$18M
Q1 2025$32M
Programs (2)
IndicationStageKey StudyRegional Status
EGFRm NSCLCAPPROVEDHERTHENA-Lung01[{"stage":"APPROVED","region":"US","approval_date":"2024-10-25"}]
NSCLCPHASE3HERTHENA-Lung02[{"stage":"APPROVED","region":"US","approval_date":"2024-10-25"}]
Notes
First-in-class HER3-directed ADC. Approved for EGFR-mutant NSCLC post-TKI and platinum. Phase 3 HERTHENA-Lung02 ongoing for 2L. Part of Merck $22B deal.
Data from Supabase · Updated 2026-03-24